Tariff Shock Threatens $200B U.S. MedTech Market: iData Research Warns of Major Supply Chain and Pricing Fallout

VANCOUVER, BC, June 2, 2025 /PRNewswire/ - As new U.S. tariffs hit medical devices and equipment, raw materials, and essential components, iData Research warns of significant cost escalation and supply disruption across the MedTech sector. A recent U.S. court decision blocking the bulk of the proposed tariffs has only added further uncertainty, leaving manufacturers and suppliers navigating shifting trade policies with little clarity.

With import duties potentially reaching up to 145%, and the potential expansion into pharmaceuticals, industry stakeholders must now reevaluate supplier networks, procurement models, and risk exposure across a $200B ecosystem.

Visit iData's market reports to help identify which devices may be the most vulnerable to tariff hikes.

"With the U.S. medical device and pharmaceutical sectors highly dependent on global supply chains, tariff volatility is triggering real consequences, from procurement delays to pricing spikes," said Dr. Kamran Zamanian, CEO of iData Research. "In today's trade environment, protecting margins in the $200B MedTech industry requires contingency planning, supplier diversification, and close monitoring of policy changes."

What's Being Tariffed and Why It Matters

Since early 2025, the U.S. has imposed tariffs on a broad range of medical imports and components, including:

• Medical devices: Surgical instruments, diagnostic equipment, and infusion systems are often produced internationally. Around 69% of medical devices marketed in the U.S. are manufactured outside the country, with approximately 14% coming from China.
• Key materials: Including titanium, stainless steel, and polymers used in implantable and surgical devices. These materials are essential for orthopedic implants, spinal devices, and various surgical tools.
• Electronic subassemblies: Like lenses, microchips, and power modules used in capital equipment, semiconductors are essential to medical devices. Taiwan, home to the world's leading semiconductor manufacturers, produces a significant share of advanced chips. While the U.S. announced a 32% tariff on Taiwanese imports, semiconductors have reportedly been exempt from these duties.
• High-volume consumables: Essential medical supplies such as syringes, gloves, masks, and gowns play a crucial role in daily healthcare operations. As of May 2024, the U.S. imported $14.9 billion in medical equipment, with some items facing increased tariffs.
• Active pharmaceutical ingredients (APIs): Primarily sourced from China and India. While pharmaceutical products were initially exempted from tariffs, there is an ongoing national security investigation that may lead to trade restrictions and the imposition of tariffs on these critical components.

Tariff rates vary widely, starting at 10% and reaching up to 145% on certain Chinese imports. Additionally, exemptions under the United States-Mexico-Canada Agreement (USMCA) remain unstable, adding uncertainty to North American supply chains.

Key Takeaways for MedTech Professionals

• Evolving Supply Chain Dynamics: As tariff frameworks evolve, companies with exposure to China-based manufacturing may benefit from re-evaluating their supplier networks, particularly for critical device components.
• Materials Pricing Volatility: Global fluctuations in the cost of titanium, stainless steel, and polymers are beginning to influence margins across spine, ortho, and cardiovascular portfolios. Adjustments in sourcing or pricing models may be necessary as these shifts unfold.
• Pharma Inputs Under Review: With APIs facing potential Section 232 tariffs, manufacturers in the drug and device overlap space may encounter new cost pressures or delays, especially those relying on Chinese or Indian ingredients.
• USMCA Ambiguity Remains: Despite regional trade agreements, recent inconsistencies in tariff enforcement are prompting some North American manufacturers to reconsider product categorization and regional diversification strategies.

iData's custom consulting services help medical device companies and product and marketing managers reveal untapped insights in overlooked or emerging markets.

Monitoring the Ripple Effect

iData Research continues to track how tariff volatility is reshaping the medical device and pharmaceutical industries, including its impact on:

• Spinal Implants & VCF Devices
• Orthopedic Trauma & Joint Reconstruction
• Cardiovascular & Vascular Access Markets
• Minimally Invasive Surgical Platforms

Produced by iData Research, a leader in MedTech market intelligence, this analysis outlines which device categories and components may be most impacted under recent U.S. tariffs.

Made for MedTech leaders, buyers, and policy makers, it points out which products and materials may be most at risk, helping teams stay informed and prepare for rising costs or supply chain issues.

Who Should Stay Informed About Medical Tariffs Exposure?

iData's market data is designed for marketing managers, CEOs, CFOs, as well as strategic decision-makers within medical device companies looking to make data-driven decisions in the volatile yet growing medical devices market.

About iData Research

iData Research has been a leader in market intelligence for the medical device industry for over 20 years, delivering data-driven insights that help companies mitigate market risks, optimize pricing strategies, and uncover new revenue opportunities.

Learn more at https://idataresearch.com/

SOURCE iData Research Inc.